Evidence map›Paper›PMID 40132139›Full record

ArticleEndocrine connections2025

Luteal phase oral dexamethasone administration alters endometrial steroid milieu.

Natalie Z M Homer, Moira Nicol, Mayank Madhra, Gregorio Naredo-Gonzalez, Sofia Laforest, Ov D Slayden, Stephen G Hillier, Brian R Walker, Pamela Warner, Ruth Andrew and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Natalie Z M HomerMass Spectrometry Core, Edinburgh Clinical Research Facility, and University/BHF Centre for Cardiovascular Science, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, UK.ORCID 0000-0002-9262-2098
Moira NicolCentre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
Mayank MadhraSimpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, Edinburgh, UK.
Gregorio Naredo-GonzalezCentre for Cardiovascular Science, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, UK.
Sofia LaforestMass Spectrometry Core, Edinburgh Clinical Research Facility, and University/BHF Centre for Cardiovascular Science, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, UK.
Ov D SlaydenOregon National Primate Research Center, Beaverton, Oregon, USA.
Stephen G HillierCentre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
Brian R WalkerTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Pamela WarnerUsher Institute of Population Health Sciences & Informatics, University of Edinburgh, Edinburgh, UK.
Ruth AndrewCentre for Cardiovascular Science, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, UK.
Hilary O D CritchleyCentre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-1913-4044

Funding

Wellcome Trust
6 · The paper itself

Abstract

We previously published the DexFEM trial, which showed that in women with heavy menstrual bleeding (HMB), oral dexamethasone reduces menstrual blood loss. Here, we report a pharmacodynamic analysis exploring the likely mechanism for this effect. We studied oral dosing with dexamethasone during the mid-luteal phase of two menstrual cycles (1.5 mg daily, 5 days) in five women with HMB (six recruited aged 41–50 years, one withdrew before treatment). Steroid hormones were profiled in serum and endometrium by liquid chromatography-tandem mass spectrometry (LC-MS/MS). We found that following oral dosing, dexamethasone reached the endometrium and that, compared to the preceding control cycle, cortisol (active), cortisone (inactive) and intermediate 11-deoxycortisol were reduced in all samples assessed, both endometrial (n = 4) and serum (n = 5). Concentrations of androgens, androstenedione and testosterone were reduced in serum but not in all tissue samples. This proof-of-concept pharmacodynamic study supports the inference that dexamethasone is effective in HMB by altering endometrial glucocorticoid concentrations.

Identifiers

PMID40132139
PMCPMC12007876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.